Although arthralgia is a significant side effect of ARO inhibitor treatment for breast cancer, patients develop joint pain only after weeks of treatment with no report of symptoms for cutaneous hyperalgesia (Henry et al., 2008, 2014; Shi et al., 2013). This evidence concerns the gene CYP19A1 and breast cancer.